Xeris Biopharma Holdings, Inc. XERS Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s total costs & expenses?
- Xeris Biopharma Holdings, Inc. (XERS) reported total costs & expenses of $75.21M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s total costs & expenses changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s total costs & expenses increased by 19.0% year-over-year, from $63.21M to $75.21M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total costs & expenses?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s total costs & expenses has grown at a 12.8% compound annual growth rate (CAGR), from $164.75M to $266.95M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating costs incurred by the company to support its primary business activities, including cost of goods sold, research and development, and selling, general, and administrative expenses. It serves as a comprehensive measure of the resources consumed to generate revenue and maintain corporate operations. Monitoring this figure helps investors evaluate the company's operational efficiency and cost management discipline.